Advertisement

Topics

Aradigm Corporation and Grifols S.A. Company Profile

12:05 EDT 23rd June 2018 | BioPortfolio

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. Aradigm has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and prevention of respiratory and other diseases in tobacco smokers through smoking cessation.


News Articles [149 Associated News Articles listed on BioPortfolio]

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

Further evidence is required to warrant approval according to the US regulator

FDA Nixes Aradigm’s Inhaled Antibiotic, Asks for New Clinical Trial

Aradigm’s attempt to commercialize an inhalable version of a generic antibiotic as a treatment for chronic lung infections has stalled with the FDA’s rejection of the company’s drug approval app...

BRIEF—EMA to review Aradigm's appliation for Linhaliq

California’s Aradigm says the European Medicines Agency is to proceed with reviewing the firm’s application…

Aradigm seeks EU nod for noncystic fibrosis lung infection drug

A marketing application was filed by Aradigm in Europe for Linhaliq, or ciprofloxacin for inhalation, which is being develope -More- 

Strong 1st-qtr showing for Spain’s Grifols

Spanish drugmaker Grifols has reported first-quarter 2018 financial results, with 1.02 billion euros…

Another FDA blow for Aradigm sees shares slump nearly 40%

US specialty drug firm Aradigm saw its shares plummet at much as 39% to $1.36 in morning trading on Monday,…

EMA to review Aradigm's lung infection drug

The European Medicines Agency accepted for review Aradigm's Linhaliq, or liposomal ciprofloxacin, which is being developed as -More- 

US FDA serves Aradigm CRL, Phase III data wanted

The US FDA has recommended Aradigm Corporation conduct an additional Phase III trial before resubmitting a new drug application for Linhaliq.

PubMed Articles [0 Results]

None

Clinical Trials [7 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to Hemostasis

The purpose of this study is to evaluate the safety and hemostasis effectiveness of human plasma-derived fibrin sealant Grifols (FS Grifols) in peripheral vascular surgery.

Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Subjects

This is a prospective, randomized, active-controlled, single-blind, parallel group clinical trial to evaluate the safety and efficacy of FS Grifols as an adjunct to hemostasis during surge...

Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Open Surgeries

This purpose of this clinical trial is to study the safety and efficacy of Topical Thrombin (Human) Grifols as an add-on treatment to help stop bleeding during vascular, parenchymous tissu...

Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura

The purpose of this study is to determine whether IGIV3I 10% Grifols is effective in the treatment of immune thrombocytopenic purpura.

IGIV Study for Chronic ITP Patients Ages 3-70

Idiopathic (immune) thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by platelet destruction and thrombocytopenia (peripheral blood platelet count < 150 x 10(9)/L). ...

Companies [182 Associated Companies listed on BioPortfolio]

Aradigm Corporation and Grifols S.A.

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of sever...

Grifols Biomat USA

Grifols Biomat USA is part of a large a network of plasma collection centers owned and operated by Grifols, a global healthcare company headquartered in Barcelona, Spain. Today, Grifols' plasma t...

Grifols

Grifols has been present in the field of healthcare since 1940 creating innovative products and services based on the values of ethics and responsibility. Over the decades, Grifols has contributed sig...

Grifols S.A.

Grifols S.A. is a Spain-based company in the healthcare sector involved in the research, development, manufacturing and marketing of plasma therapies, IV therapy solutions, enteral and parenteral nutr...

Grifols, Inc.

Currently, we supply plasma products, diagnostic reagents, automated analyzers and dosing machines.In 1998, Grifols established a joint venture with a US diagnostic company, Quest International. Then,...

More Information about "Aradigm Corporation and Grifols S.A." on BioPortfolio

We have published hundreds of Aradigm Corporation and Grifols S.A. news stories on BioPortfolio along with dozens of Aradigm Corporation and Grifols S.A. Clinical Trials and PubMed Articles about Aradigm Corporation and Grifols S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aradigm Corporation and Grifols S.A. Companies in our database. You can also find out about relevant Aradigm Corporation and Grifols S.A. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Corporate Database Quicklinks



Searches Linking to this Company Record